An International Commission has been convened by the UK’s Royal Society, the US National Academy of Sciences and the US National Academy of Medicine, with the participation of academies of sciences and medicine from around the world. The commission’s aim is to develop principles, criteria and standards for the clinical use of genome editing of the human germline, should it be considered to be acceptable by society. Read more.
2nd Commission meeting
14 — 15 November 2019, London
The second meeting of the commission took place on 14 November at the National Gallery and 15 November at the Royal Society.
Catch up on the Day 1 livestream
Catch up on the Day 2 livestream.
View the agenda (PDF)
1st Commission meeting
13 August 2019, Washington, DC
The first meeting of the commission took place at the National Academy of Sciences building in Washington, DC, on 13 August 2019. Recordings and presentations from this meeting can be accessed from the US National Academies’ website.
Public call for evidence
To inform its deliberations, the commission engaged with external expertise and invited responses to a public call for evidence during September 2019. The questions used in the public call for evidence are available to download (PDF).
The US National Academies will list all written submissions in a Public Access File (PAF) established for the International Commission. These submissions will be made available to the public upon request, for more information visit the US National Academies’ website.
In addition to the public meetings, webinar presentations have been given by leading academics from around the world to inform the state of research into germline genome editing. Video recordings from each of these webinars (listed below) can be viewed from the US National Academies’ website.
15 October 2019: Webinar on validating on-target and off-target edits, featuring Jin-Soo Kim, Seoul National University.
9 October 2019: Webinar on homology directed repair and single cell genomics, featuring Shoukhrat Mitalipov, Oregon Health & Science University and Xiaoliang Sunney Xie, Peking University.
7 October 2019: Webinar on the impact of editing on embryo viability and editing spermatogonial stem cells, featuring Kathy Niakan, Francis Crick Institute and Kyle Orwig, Magee-Womens Research Institute.
4 October 2019: Webinar on informed consent in the context of germline genome editing, featuring Ellen Clayton, Vanderbilt University and Robert Klitzman, Columbia University.
This International Commission was established following the reported birth of the first genetically edited babies announced in November 2018 during the Second International Summit on Human Genome Editing in Hong Kong. This unprecedented report was criticised at the time by the summit organising committee, who recommended the development of a translational pathway for human germline editing (editing that would be inherited by subsequent generations) based upon criteria articulated in guidance documents published over the past three years.
The work of the international commission is overseen by an international oversight board, made up of leaders from national academies of sciences and international institutions. They have approved membership of the commission and its Statement of Task, and will ensure that it follows due processes. They will also approve an expert review panel for the commission’s final report including its findings and recommendations, which is expected to be issued in the spring of 2020.
The US National Academies and the Royal Society are the secretariat of the commission, which includes representatives from 10 nations. Kay Davies, professor of genetics at the MDUK Oxford Neuromuscular Centre at the University of Oxford, England, and Richard Lifton, president of the Rockefeller University in New York City, are co-chairs of the commission.